Warning: fsockopen() [function.fsockopen]: unable to connect to 193.0.6.135:43 (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038

Warning: fsockopen() [function.fsockopen]: unable to connect to 200.3.14.10:43 (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038

Warning: fsockopen() [function.fsockopen]: unable to connect to 196.216.2.21:43 (Connection refused) in /home/content/67/4046467/html/administrator/components/com_joomlastats/count.classes.php on line 1038
Home Services In Country Services

Workshops & Lectures

In country  services

 

Synergy Research conducts frequent seminars and workshops for the life science industry.  Below please find our current calendar of events.

Workshop and Lecture Series

Upcoming Workshops and Lectures provided by 

Synergy Research Inc.

 


September  2010

 

510(k) Exempt or not Exempt

Mario Guralnik, PhD, Erin Baruch, MD 

  • Workshop on navigating the FDA Medical Device Program
  • What options are really available
  • DeNovo !  
  • When do I submit


GMPs for Early Clinical Trial Programs 

Mario Guralnik, PhD, Yvette Yamanouci, PhD

  • Meaning of A Phased Approach
  • Does my Phase I Qualify
  • cGMP Statutory Requirements and the IND Program

 

 




October 2010

Medical Foods

Mario Guralnik, PhD 

  • Where do they fall?
  • What does that mean in IND land?
  • Clinical Trial Requirements
  • Can my local acting gum be a medical food?


Device Development Workshop
Mario Guralnik, PhD, Yvette Yamanouci, PhD, Erin Baruch, MD 
  • Regulatory Strategies
  • Clinical Development Plans
  • Reimbursement Studies


Good Clinical Practice; Site-to-Sponsor
Mario Guralnik, PhD, Erin Baruch, MD 
  • IRB Requirements Workshop
  • The Modern Protocol
  • Data and More Data; Dealing with Case Report Forms
  • Sponsor-CRO Integration

 

 

  

 

 

November 2010

 

505(b)(2) Development Umbrella

Mario Guralnik, PhD

  • Find out if our product has a life under the 505(b)(2) umbrella
  • What are the truths and myths about 505(b)(2) drug development programs
  • When to ask the FDA;  What to ask the FDA



The Pre-IND Process

Mario Guralnik, PhD, Yvette Yamanouci, PhD 

  • What to do about nothing:  What happens when FDA refuses to provide a pre-IND meeting
  • What you shouldn't ask can be more important than what to ask
  • My briefing package:  What that should look like

 

 

 



 

News & Events

  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>